Rchr
J-GLOBAL ID:202401012102110068
Update date: Feb. 18, 2025 Nishio Shin
ニシオ シン | Nishio Shin
Affiliation and department: Job title:
Associate Professor
Research theme for competitive and other funds (1): - 2023 - 2026 SLFN11の分子メカニズムから解き明かすDNA障害型抗がん剤の真の作用機序
Papers (407): -
Kosei Hasegawa, Shin Nishio, Kouji Yamamoto, Hiroyuki Fujiwara, Hiroya Itagaki, Tomonori Nagai, Hirokuni Takano, Satoshi Yamaguchi, Akiko Kudoh, Yurina Suzuki, et al. Tegafur-uracil Maintenance Chemotherapy Post-Chemoradiotherapy for Cervical Cancer: Randomized Trial. European Journal of Cancer. 2025
-
Seiichi Hayato, Lora Hamuro, Toshio Shimizu, Kan Yonemori, Shin Nishio, Mayu Yunokawa, Tatsuya Yoshida, Makoto Nishio, Koji Matsumoto, Kazuhiro Takehara, et al. Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. Journal of clinical pharmacology. 2025
-
Yuichi Murakami, Daisuke Katsuchi, Taichi Matsumoto, Kuon Kanazawa, Tomohiro Shibata, Akihiko Kawahara, Jun Akiba, Nozomu Yanaihara, Aikou Okamoto, Hiroaki Itamochi, et al. Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer. Scientific Reports. 2024. 14. 1. 21701-21701
-
Morio Ijichi, Kimio Ushijima, Tomohiko Yamaguchi, Naoyo Nishida, Kazuto Tasaki, Jongmyung Park, Shin Nishio, Toshiharu Kamura, Jun Akiba, Tatsuyuki Kakuma, et al. High Expression of NDRG1 is a Poor Prognostic Factor in Patients with Endometrial Endometrioid Carcinoma with Long-Term Observation. The Kurume medical journal. 2024. advpub
-
西尾 真, 鈴木 幸雄. 【-外来担当医として知っておきたい-婦人科腫瘍の卵巣機能・妊孕性温存療法】子宮体がん編 高用量MPA療法以外の妊孕性温存療法の選択肢. 臨床婦人科産科. 2024. 78. 9. 798-802
more... Return to Previous Page